REG-Millennium Partners, L.P. Form 8.3 - Horizon Therapeutics plc
03/10/2023 15:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231003:nBwcfkxsra&default-theme=true
Form 8.3 - Horizon Therapeutics plc
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR
MORE
1. KEY INFORMATION
Name of person dealing (Note 1) Millennium International Management LP
Company dealt in Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note IE00BQPVQZ61
2)
Date of dealing 2(nd) October 2023
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
(1) Relevant securities 4,604,162 4,430
(2.011%)
(0.002%)
(2) Derivatives (other than options) - 496,000
(0.217%)
(3) Options and agreements to purchase/sell 822,900 1,077,900
(0.359%)
(0.471%)
Total 5,427,062 1,578,330
(2.371%)
(0.689%)
(b) Interests and short positions in relevant securities of the company, other
than the class dealt in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (USD) (Note 5)
Purchase 7 115.78
Purchase 4 115.76
Sale 27 115.93
Purchase 89 115.84
Purchase 27 115.80
Purchase 212 115.78
Sale 101 115.78
Purchase 16 115.75
Sale 188 115.85
Purchase 824 115.76
Sale 346 115.79
Purchase 15,270 115.93
Sale 184 115.84
Purchase 200 115.80
Sale 420 115.80
Purchase 27 115.77
Sale 27 115.77
Purchase 9 115.70
Sale 6 115.89
Sale 14 115.92
Sale 18 115.88
Purchase 100 115.81
Sale 3 115.83
Sale 18 115.87
Purchase 6 115.84
Purchase 160 115.79
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit (USD)
e.g. CFD
(Note 6)
(Note 7)
(Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
e.g. call option
(USD)
(ii) Exercising
Product name, Number of securities Exercise price per unit (Note 5)
e.g. call option
(d) Other dealings (including transactions in respect of new securities) (Note
4)
Nature of transaction Details Price per unit
(Note 8)
(if applicable) (Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.
None.
Is a Supplemental Form 8 attached? (Note 9) YES
Date of disclosure 3(rd) October 2023
Contact name Stephen Glasper
Telephone number +44 203 398 2166
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)
Ap32
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES
1. KEY INFORMATION
Full name of person making Millennium International Management LP
disclosure:
Name of offeror/offeree in relation Horizon Therapeutics plc
to whose relevant securities the
disclosure relates:
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of Product Written or Number of Exercise Type Expiry
relevant
description
purchased
securities to
price
e.g.
date
security
e.g. call
which option
per unit
American,
option
or derivative
European
relates
(USD)
etc.
IE00BQPVQZ61 Put Option Purchased 300 80.00 American 1/17/2025
IE00BQPVQZ61 Put Option Purchased 100,300 90.00 American 1/19/2024
IE00BQPVQZ61 Put Option Written 284,900 60.00 American 12/15/2023
IE00BQPVQZ61 Put Option Written 100,000 65.00 American 11/17/2023
IE00BQPVQZ61 Put Option Purchased 55,000 70.00 American 1/19/2024
IE00BQPVQZ61 Put Option Written 41,500 45.00 American 1/19/2024
IE00BQPVQZ61 Put Option Purchased 250,000 85.00 American 1/19/2024
IE00BQPVQZ61 Call Option Purchased 152,500 110.00 American 11/17/2023
IE00BQPVQZ61 Call Option Purchased 4,500 110.00 American 10/20/2023
IE00BQPVQZ61 Call Option Purchased 100,000 100.00 American 12/15/2023
IE00BQPVQZ61 Call Option Written 100,000 110.00 American 12/15/2023
IE00BQPVQZ61 Call Option Written 3,400 100.00 American 10/20/2023
IE00BQPVQZ61 Call Option Purchased 2,800 100.00 American 11/17/2023
IE00BQPVQZ61 Put Option Purchased 150,000 85.00 American 11/17/2023
IE00BQPVQZ61 Put Option Purchased 2,600 90.00 American 11/17/2023
IE00BQPVQZ61 Put Option Purchased 40,900 100.00 American 11/17/2023
IE00BQPVQZ61 Put Option Purchased 41,500 65.00 American 1/19/2024
IE00BQPVQZ61 Put Option Written 600 100.00 American 10/20/2023
IE00BQPVQZ61 Put Option Purchased 100,000 70.00 American 11/17/2023
IE00BQPVQZ61 Call Option Purchased 200 115.00 American 12/15/2023
IE00BQPVQZ61 Put Option Written 100,000 60.00 American 1/19/2024
IE00BQPVQZ61 Call Option Purchased 35,200 110.00 American 1/19/2024
IE00BQPVQZ61 Call Option Written 54,800 115.00 American 1/19/2024
IE00BQPVQZ61 Call Option Written 400 105.00 American 11/17/2023
IE00BQPVQZ61 Put Option Written 400 105.00 American 11/17/2023
IE00BQPVQZ61 Put Option Purchased 27,000 95.00 American 10/20/2023
IE00BQPVQZ61 Call Option Purchased 300 115.00 American 11/17/2023
IE00BQPVQZ61 Put Option Purchased 11,800 115.00 American 11/17/2023
IE00BQPVQZ61 Put Option Purchased 5,300 115.00 American 11/17/2025
IE00BQPVQZ61 Put Option Purchased 5,600 115.00 American 1/19/2024
IE00BQPVQZ61 Put Option Purchased 115,000 115.00 American 10/20/2023
IE00BQPVQZ61 Put Option Purchased 11,400 115.00 American 12/15/2023
IE00BQPVQZ61 Put Option Purchased 600 115.00 American 2/16/2023
IE00BQPVQZ61 Put Option Purchased 600 115.00 American 3/15/2024
IE00BQPVQZ61 Put Option Purchased 400 115.00 American 5/17/2023
IE00BQPVQZ61 Put Option Purchased 1,000 115.00 American 10/27/2023
3. AGREEMENTS TO PURCHASE OR SELL
Full details should be given so that the nature of the interest or position
can be fully understood:
Ap33
4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER
EMPLOYEE OPTIONS)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
It is not necessary to provide details on a Supplemental Form with regard to
cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in
doubt, consult the Panel.
References in these notes to “the Rules” are to the Irish Takeover Panel
Act, 1997, Takeover Rules, 2022.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20231003643945/en/
(https://www.businesswire.com/news/home/20231003643945/en/)
Millennium Partners, L.P.
Copyright Business Wire 2023Recent news on Horizon Therapeutics
See all newsREG - BlackRock Group Horizon Therapeutics - Form 8.3 - Horizon Therapeutics plc
AnnouncementREG - Hudson Bay Capital Horizon Therapeutics - Form 8.3 - Horizon Therapeutics Plc
AnnouncementREG - Societe Generale SA Horizon Therapeutics - Form 8.3 - Horizon Therapeutics Plc
AnnouncementREG - Hudson Bay Capital Horizon Therapeutics - Form 8.3 - Horizon Therapeutics Plc
AnnouncementREG - BlackRock Group Horizon Therapeutics - Form 8.3 - Horizon Therapeutics plc
Announcement